Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Buechner
Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Elara: A Phase 2 Trial Investigating the Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory/Relapsed Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Ibrutinib + Chemoimmunotherapy (Cit) for Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (B-Nhl) in Children (Sparkle Trial): Initial Safety, Pk, and Efficacy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Long-Term Outcome of Patients With Relapsed/Refractory B-Cell Non- Hodgkin Lymphoma Treated With Bispecific Antibody Blinatumomab in a Phase I Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
